Abstract
Inflammatory bowel disease has shifted from the peripheral area of gastroenterology to the center of its interest for the last half century. Undoubtedly, two major factors made a contribution to it.
First of all, there is a dramatic increase in the incidence of these diseases along with a shift to younger age at onset that is evident not only in countries with a traditionally high incidence. Secondly, there have been therapeutic advances made in recent decades, that on the other hand bring new pharmaco-economic requirements.
The social status of the patients with inflammatory bowel disease has changed, the demands on gastroenterologist's education in this field have increased, and as we quickly expand our knowledge, the publications are getting out of date. Despite all advances, the treatment of inflammatory bowel disease remains symptomatic.
It is not only about the new guidelines, but also about historical respect and humility when dealing with information that should primarily serve as the entire medical science to our patients. The authors would like to follow such an approach.